Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PulmoStem
- Development stage
- Phase 1
- Lead developer
- Magle
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
AmnioPul-02 (PulmoStem) is an allogeneic, lung-specific mesenchymal stem cell (MSC) therapy derived from human amniotic fluid. Developed by the Swedish biopharmaceutical company Amniotics AB, the therapy consists of neonatal-quality MSCs selected for their high proliferative capacity and specific lung-homing properties. It is primarily being developed to treat inflammatory and fibrotic lung conditions, including COVID-19-related Acute Respiratory Distress Syndrome (ARDS) and other viral lower respiratory tract infections. The cells function by secreting immunomodulatory and anti-inflammatory factors that reduce pulmonary inflammation and promote tissue regeneration, potentially preventing the progression to chronic lung fibrosis. The therapy is administered via intravenous infusion.
- Brand names
- PulmoStem
- Other names
- AmnioPul-02AmnioPul02AmnioPul 02
Beyond the preview
Go deeper on PulmoStem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PulmoStem.